According to Zhitong Finance App News, Dingdang Health (09886) announced its annual results for the year ended December 31, 2023. The group obtained revenue of RMB 4.857 billion (same unit), an increase of 12.2% year over year; company owners should have accounted for losses of RMB 226 million during the year, a decrease of 92% year over year; adjusted net loss of RMB 107 million, a decrease of 17.2% year on year; loss per share.
In the year ended December 31, 2023, the company's total revenue increased to 4.857 billion yuan (2022:4.329 billion yuan), an increase of 12.2% over the previous year; registered users and medical consultation services grew simultaneously, with a cumulative total of 41.5 million registered users, and obtained 8.21 million health consultations and consultations in the online consultation business. In the year ended December 31, 2023, the company's net loss level narrowed by 91.9%, a year-on-year loss of 2,611 billion yuan, and achieved a loss of 231 million yuan. The adjusted loss rate was 2.2%, a decrease of 0.8 percentage points over the previous year, mainly due to the company's cost reduction and efficiency management strategy, which effectively improved operational efficiency.
Dingyi Health will always be user-centered, build a “medical, testing, drug, and insurance” ecosystem through deep cooperation and empowerment in the industrial chain, and focus on residents' health needs, closely follow national policy guidance, focus on forward-looking innovation, steady layout and actively promote business sectors including online medical insurance payments, professional pharmaceutical cold chain instant home service, AI smart medical services, etc., to provide residents with professional, safe, immediate and efficient medicine and medical services. At the same time, it will also further consolidate and develop the instant health-to-home business in megacities, focus on the cryptographic layout of core cities, and steadily develop new cities to support the company's medium- to long-term scale growth.